Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 16/20 | 0.59 |
| ▸ | LOX | P28300 | 9/20 | 0.59 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30398543 | 1.00 | LOXL2 (0.59) | LOXL2LOXLOXL3EPHX2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL22287295 | 0.98 | LOXL2 (0.60) | LOXL2LOXLOXL3EPHX2 | |
| Hydrochloric Acid SCHEMBL4770701 | 0.98 | LOXL2 (0.57) | LOXL2LOXLOXL3EPHX2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4770707 | 0.98 | LOXL2 (0.60) | LOXL2LOXLOXL3EPHX2 | |
| SCHEMBL30931697 | 0.87 | LOXL2 (0.56) | LOXL2LOXLOXL3 | |
| SCHEMBL30931725 | 0.87 | LOXL2 (0.60) | LOXL2LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL25200556 | 0.85 | LOXL2 (0.58) | LOXL2LOXLOXL3 | |
| SCHEMBL4343502 | 0.83 | LOXL2 (0.56) | LOXL2LOXLOXL3 | |
| SCHEMBL15670435 | 0.83 | RECQL (0.46) | LOXL2LOXEPHX2ALDH1A1MAPT | |
| SCHEMBL18083226 | 0.83 | NOS3 (0.46) | LOXL2LOXEPHX2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630404-A1 | UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| EP-4630406-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| US-20250282725-A1 | KCNQ POTENTIATORS | Eii Lilly and Company | 2025-09-11 | — | — | US | disclosed |
| US-12344584-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| EP-4452944-A1 | CYCLOPROPYL COMPOUNDS | Icagen, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2024-10-10 | — | — | US | disclosed |
| EP-4433453-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | Icagen, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024121046-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121048-A1 | UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| CN-113692304-A | 1- ((2- (2,2, 2-trifluoroethoxy) pyridin-4-yl) methyl) urea derivatives as KCNQ enhancers | 礼来公司 | 2021-11-23 | — | — | CN | disclosed |
| WO-2020163268-A1 | 1-((2-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-4-YL)METHYL)UREA DERIVATIVES AS KCNQ POTENTIATORS | ELI LILLY AND COMPANY (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163268-A1 | 1-((2-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-4-YL)METHYL)UREA DERIVATIVES AS KCNQ POTENTIATORS | ELI LILLY AND COMPANY (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247752-A1 | KCNQ Potentiators | ELI LILLY AND COMPANY (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200247752-A1 | KCNQ Potentiators | ELI LILLY AND COMPANY (US) | 2020-08-06 | — | — | US | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| WO-2012152983-A1 | PHENYL- SULFONYL DERIVATIVES AS MEDIATORS OF TRPA1 RECEPTOR ACTIVITY FOR THE TREATMENT OF PAIN | ORION CORPORATION (FI) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282725-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A43, F12 | LOXL2 3167/4885LOX 3544/4885LOXL3 1161/4885 |
| US-20200247752-A1 | KCNQ Potentiators | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-12344584-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | LOXL2 2082/4885LOX 2625/4885LOXL3 2030/4885 |
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR1 | LOXL2 4525/4885LOX 4419/4885LOXL3 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.